TRIUMPH: phase II trial of rucaparib monotherapy in patients with metastatic hormone-sensitive prostate cancer harboring germline homologous recombination repair gene mutations.
Mark C MarkowskiCora N SternbergHao WangTingchang WangLaura LinvilleCatherine H MarshallRana SullivanSerina KingTamara L LotanEmmanuel S AntonarakisPublished in: The oncologist (2024)
Rucaparib can induce clinical responses in a biomarker-selected metastatic prostate cancer population without concurrent ADT. However, the pre-specified efficacy threshold was not met, and enrolment was truncated. Although durable responses were observed in a subset of patients, further study of PARPi treatment without ADT in mHSPC is unlikely to change clinical practice.
Keyphrases
- prostate cancer
- dna repair
- radical prostatectomy
- clinical practice
- end stage renal disease
- dna damage
- ejection fraction
- newly diagnosed
- squamous cell carcinoma
- chronic kidney disease
- open label
- combination therapy
- prognostic factors
- clinical trial
- randomized controlled trial
- locally advanced
- radiation therapy
- rectal cancer